The incidence of HER2-positive (HER2+) breast cancer decreases with advancing age yet impacts a substantial proportion of patients diagnosed with breast cancer aged 70 or older, affecting approximately 11% of individuals in this age group [77]. This evidence concerns the gene ERBB2 and breast cancer.